Preserved bevacizumab (Avastin®) eye drops for application in multidose containers - an in-vitro characterisation.

ABSTRACT:

Purpose

Monoclonal antibodies have made an immense contribution to the treatment of various human diseases. We aimed at investigating an affordable treatment option for veterinary patients with corneal neovascularization by adding the preservative benzalkonium chloride (BAC) to bevacizumab (Avastin®) for usage in multidose containers. A comprehensive analytical similarity assessment of preserved and unpreserved bevacizumab after dilution and storage was carried out.

Methods

Diluted and preserved bevacizumab was analysed at different time points for a 4-week period and compared with unpreserved bevacizumab at the same concentrations at each time point. Native-PAGE, immunoblotting and HP-SEC were used to observe aggregation and degradation. DLS provided information about parti

SUBMITTER: Lessiak U 

PROVIDER: S-EPMC11871757 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature